Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 19/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18626100 | 0.86 | BRAF (0.41) | BRAFMAPK14DYRK1ADYRK2DYRK1B | |
| SCHEMBL8242894 | 0.83 | DYRK1B (0.36) | BRAFDYRK1ADYRK2DYRK1B | |
| SCHEMBL1554769 | 0.80 | BRAF (0.46) | BRAFMAPK14 | |
| SCHEMBL15172107 | 0.80 | DYRK1A (0.38) | BRAFMAPK14DYRK1ADYRK1B | |
| SCHEMBL15152570 | 0.80 | DYRK1B (0.39) | BRAFDYRK1ADYRK2DYRK1B | |
| SCHEMBL8228308 | 0.79 | BRAF (0.39) | BRAFMAPK14DYRK1A | |
| SCHEMBL8226709 | 0.79 | BRAF (0.37) | BRAFMAPK14DYRK1A | |
| SCHEMBL8232601 | 0.79 | BRAF (0.48) | BRAFMAPK14DYRK1A | |
| SCHEMBL2959275 | 0.78 | DYRK1A (0.36) | BRAFMAPK14DYRK1ADYRK2DYRK1B | |
| SCHEMBL2051001 | 0.77 | BRAF (0.44) | BRAFMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49556-E1 | Compounds and compositions as protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-RE49556-E1 | Compounds and compositions as protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230116233-A1 | Compounds And Compositions As Protein Kinase Inhibitors | ARRAY BIOPHARMA INC (US) | 2023-04-13 | — | — | US | disclosed |
| US-20200323852-A1 | Compounds And Compositions As Protein Kinase Inhibitors | IRM LLC (BM) | 2020-10-15 | — | — | US | disclosed |
| US-20200323852-A1 | Compounds And Compositions As Protein Kinase Inhibitors | IRM LLC (BM) | 2020-10-15 | — | — | US | disclosed |
| US-10576080-B2 | Compounds and compositions as protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10576080-B2 | Compounds and compositions as protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10568884-B2 | Compounds and compositions as protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10568884-B2 | Compounds and compositions as protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20180297985-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2018-10-18 | — | — | US | disclosed |
| WO-2011025927-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | WO | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-2183243-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | Pfizer Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200323852-A1 | Compounds And Compositions As Protein Kinase Inhibitors | BRAF, RAF1, ARAF | BRAF 1/4885MAPK14 200/4885DYRK1A 1889/4885 |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | BRAF, RAF1, NRAS | BRAF 1/4885MAPK14 117/4885DYRK1A 1638/4885 |
| US-10568884-B2 | Compounds and compositions as protein kinase inhibitors | BRAF, RAF1, ARAF | BRAF 1/4885MAPK14 200/4885DYRK1A 1889/4885 |
| US-20180297985-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | BRAF, RAF1, ARAF | BRAF 1/4885MAPK14 200/4885DYRK1A 1889/4885 |
| US-20230116233-A1 | Compounds And Compositions As Protein Kinase Inhibitors | BRAF, RAF1, ARAF | BRAF 1/4885MAPK14 200/4885DYRK1A 1889/4885 |
| US-10576080-B2 | Compounds and compositions as protein kinase inhibitors | BRAF, RAF1, ARAF | BRAF 1/4885MAPK14 200/4885DYRK1A 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.